What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Antibody
His main research concerns Antigen, T cell, Cytotoxic T cell, T-cell receptor and CD8.
The various areas that he examines in his Antigen study include Cell, Monoclonal antibody and Molecular biology.
In the subject of general Cytotoxic T cell, his work in CD28 is often linked to Size heterogeneity, thereby combining diverse domains of study.
The concepts of his T-cell receptor study are interwoven with issues in Superantigen, T lymphocyte, Toxin, Microbiology and Major histocompatibility complex.
His work focuses on many connections between Superantigen and other disciplines, such as Virology, that overlap with his field of interest in Lymphoma and CD19.
His CD8 study is concerned with the larger field of Immunology.
His most cited work include:
- Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy" (709 citations)
- V beta-specific stimulation of human T cells by staphylococcal toxins (637 citations)
- The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. (371 citations)
What are the main themes of his work throughout his whole career to date?
David N. Posnett mainly focuses on Immunology, Molecular biology, Antigen, Virology and T cell.
David N. Posnett usually deals with Molecular biology and limits it to topics linked to Monoclonal antibody and Immunofluorescence and Phenotype.
His specific area of interest is Antigen, where David N. Posnett studies Major histocompatibility complex.
His work deals with themes such as Cell culture, Superantigen and In vitro, which intersect with Virology.
His biological study spans a wide range of topics, including Cytotoxic T cell and B-cell receptor, B cell.
His research in T-cell receptor focuses on subjects like Human leukocyte antigen, which are connected to Gene expression.
He most often published in these fields:
- Immunology (41.84%)
- Molecular biology (40.82%)
- Antigen (32.65%)
What were the highlights of his more recent work (between 1998-2009)?
- Immunology (41.84%)
- Virology (34.69%)
- Cytotoxic T cell (19.39%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Immunology, Virology, Cytotoxic T cell, Antigen and T cell.
His Virology study combines topics from a wide range of disciplines, such as Immediate early protein and ANTIGENS CD.
His work in Cytotoxic T cell addresses issues such as CD8, which are connected to fields such as Molecular biology.
His Antigen research includes elements of Allele and Genetic predisposition.
His T lymphocyte research integrates issues from Cerebrospinal fluid, CD3 and IL-2 receptor.
His T-cell receptor research incorporates themes from Genotype, Genotyping, Haplotype and Antibody.
Between 1998 and 2009, his most popular works were:
- Differentiation of human CD8 T cells: implications for in vivo persistence of CD8+ CD28- cytotoxic effector clones. (191 citations)
- Superantigens in Human Disease (44 citations)
- Herpesviruses and autoimmunity. (42 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Antibody
David N. Posnett mainly investigates Immunology, Cytotoxic T cell, T cell, Virology and Multiple sclerosis.
His Pathogenesis and Superantigen study in the realm of Immunology interacts with subjects such as Toxic shock syndrome.
His Cytotoxic T cell research is multidisciplinary, relying on both Human leukocyte antigen, CD8 and Antigen.
David N. Posnett combines subjects such as Ex vivo, Cellular differentiation and Molecular biology with his study of Antigen.
His T cell study integrates concerns from other disciplines, such as Receptor, Gene expression, Gene and Lytic cycle.
His Multiple sclerosis study incorporates themes from T lymphocyte, Cerebrospinal fluid, IL-2 receptor, CD3 and Autoimmune Process.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
